AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 121 min read$CERS

BJERKHOLT ERIC sold $53K of CERS

BJERKHOLT ERIC sold 20,454 shares of CERUS CORP (CERS) at $2.60 on 2026-06-09.

Original reporting
SEC EDGAR · BJERKHOLT ERIC
Published Jun 12, 2026, 1:17 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 12, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CERS
Neutral
high confidence
Mentioned
$CERS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CERSNeutralLow
01

Why it matters

The disclosure updates the record of insider ownership and may slightly influence sentiment, but it does not introduce new operational or regulatory information in the provided text.

02

Market read

A newly filed insider sale provides incremental information on insider behavior, but lacks accompanying fundamental catalysts.

03

What to watch

Traders may watch whether additional insiders file similar sales soon, or whether the sale price ($2.60) differs materially from recent trading levels (not provided here).

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-11 for a 2026-06-09 sale

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for Cerus Corp.

Company-level read

Ticker impact

$CERSNeutralHigh confidence
Context

Director Eric Bjerkholt sold 20,454 shares of Cerus Corp on 2026-06-09 at $2.60/share via an open-market sale (Form 4).

Expected impact

Low near-term impact; any reaction is likely muted unless selling accelerates or coincides with other negative disclosures.

Evidence & confidence

The filing is a primary-source insider transaction, but it is not accompanied here by new company fundamentals (no guidance, trial, or regulatory update).

Market effects

Sector

No sector read-through; this is a single-company insider transaction with no additional sector datapoints.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification or liquidity needs; without a 10b5-1 plan and with a small-to-moderate size, it may not reflect bearish fundamentals.

Key entities

  • issuer
    CERUS CORP

    Company whose director insider sale is disclosed on Form 4.

  • insider
    BJERKHOLT ERIC

    Director who executed an open-market sale of 20,454 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CERS insider trading history →

Related articles

NOV 3
$CERSMed

Cerus Q3 Earnings Call Highlights

Cerus reported Q3 EMEA revenue growth of 5%, impacted by geopolitical and currency headwinds. The company's RedeS study met primary efficacy endpoints, with full analysis expected soon. Cerus reaffirmed 2026 revenue guidance of $229M-$231M and reported positive adjusted EBITDA. The company is addressing regulatory questions from the FDA and ANSM. Cerus aims for GAAP profitability and plans to refresh its shelf registration statement.

finance.yahoo.com2 min
NOV 2
$CERSMed

Cerus: Q3 Earnings Snapshot

Cerus Corp. reported a Q3 loss of $550,000, or less than 1 cent per share, with revenue of $57.7 million. The company expects full-year revenue between $229 million and $231 million.

finance.yahoo.com1 min
NOV 2
$CERSMedAI 8/10

Cerus' blood-safety system meets main goal in late-stage trial

Cerus Corp reported that its Intercept blood-safety technology met the main goal in a late-stage trial, showing treated red blood cells performed as well as conventional ones in transfusions. The study found no significant difference in adverse events, though some patients developed temporary antibodies. The technology is not yet FDA-approved.

finance.yahoo.com4 min
NOV 2
$CERSMed

Cerus Corporation Announces Third Quarter 2026 Financial Results

CERUS CORP (CERS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cerus Corporation Announces Third Quarter 2026 Financial Results Third quarter 2026 total revenue of $64.0 million; third quarter 2026 product revenue of $57.7 million, +10% Y/Y Announced positive topline Phase 3 RedeS results of the INTERCEPT Blood System for red bl

SEC EDGAR 8-K2 min
NOV 2
MedAI 8/10

Treated red blood cells performed no worse than conventional cells on hemoglobin gains in Cerus’ Phase 3 trial.

Cerus Corporation reported that its INTERCEPT Red Blood Cells (RBCs) met the primary efficacy endpoint in a Phase 3 trial, showing non-inferiority to conventional RBCs in adjusted hemoglobin increment. The study also met primary safety endpoints, with no significant differences in treatment-emergent adverse events between the treatment and control arms. Cerus plans to submit full study results for peer-reviewed publication and presentation at scientific meetings.

stocktitan.net2 min